With a major product approval and launch in its sights, Dexcom prepares for a big year in 2022.
Across 2021, Dexcom (NSDQ:DXCM) took several steps forward.
The company touted its next-generation G7 continuous glucose monitor (CGM) and announced a major regulatory nod and partnership for real-time application programming interfaces (APIs), to list a couple.
As the new year gets underway, expectations for the coming year have been set even higher.
“2022 holds about more activity than we’ve ever seen in a given year,” Sayer told Drug Delivery Business News. “It’s going to be a year of many of the same activities, but some very big advances on the product front. And then, once we get the hardware platforms out there, we’re hopeful we can then start coming up with several software solutions that are going to be different than what we’ve had in the past. It’s going to be a fun year.”